HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
Herpes simplex virus 1 (HSV-1) provides a genetic chassis for several oncolytic viruses (OVs) currently in clinical trials. Oncolytic HSV1 (oHSV) have been engineered to reduce neurovirulence and enhance anti-tumor lytic activity and immunogenicity to make them attractive candidates in a range of on...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/12/3514 |
id |
doaj-990f466362a04edab2ebb1b847708440 |
---|---|
record_format |
Article |
spelling |
doaj-990f466362a04edab2ebb1b8477084402020-11-27T08:07:39ZengMDPI AGCancers2072-66942020-11-01123514351410.3390/cancers12123514HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical TrialsMarilin S. Koch0Sean E. Lawler1E. Antonio Chiocca2Harvey Cushing Neurooncology Research Laboratories, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAHarvey Cushing Neurooncology Research Laboratories, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAHarvey Cushing Neurooncology Research Laboratories, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAHerpes simplex virus 1 (HSV-1) provides a genetic chassis for several oncolytic viruses (OVs) currently in clinical trials. Oncolytic HSV1 (oHSV) have been engineered to reduce neurovirulence and enhance anti-tumor lytic activity and immunogenicity to make them attractive candidates in a range of oncology indications. Successful clinical data resulted in the FDA-approval of the oHSV talimogene laherparepvec (T-Vec) in 2015, and several other variants are currently undergoing clinical assessment and may expand the landscape of future oncologic therapy options. This review offers a detailed overview of the latest results from clinical trials as well as an outlook on newly developed HSV-1 oncolytic variants with improved tumor selectivity, replication, and immunostimulatory capacity and related clinical studies.https://www.mdpi.com/2072-6694/12/12/3514HSV-1oncolytic virusimmunotherapyclinical trials |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marilin S. Koch Sean E. Lawler E. Antonio Chiocca |
spellingShingle |
Marilin S. Koch Sean E. Lawler E. Antonio Chiocca HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials Cancers HSV-1 oncolytic virus immunotherapy clinical trials |
author_facet |
Marilin S. Koch Sean E. Lawler E. Antonio Chiocca |
author_sort |
Marilin S. Koch |
title |
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials |
title_short |
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials |
title_full |
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials |
title_fullStr |
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials |
title_full_unstemmed |
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials |
title_sort |
hsv-1 oncolytic viruses from bench to bedside: an overview of current clinical trials |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-11-01 |
description |
Herpes simplex virus 1 (HSV-1) provides a genetic chassis for several oncolytic viruses (OVs) currently in clinical trials. Oncolytic HSV1 (oHSV) have been engineered to reduce neurovirulence and enhance anti-tumor lytic activity and immunogenicity to make them attractive candidates in a range of oncology indications. Successful clinical data resulted in the FDA-approval of the oHSV talimogene laherparepvec (T-Vec) in 2015, and several other variants are currently undergoing clinical assessment and may expand the landscape of future oncologic therapy options. This review offers a detailed overview of the latest results from clinical trials as well as an outlook on newly developed HSV-1 oncolytic variants with improved tumor selectivity, replication, and immunostimulatory capacity and related clinical studies. |
topic |
HSV-1 oncolytic virus immunotherapy clinical trials |
url |
https://www.mdpi.com/2072-6694/12/12/3514 |
work_keys_str_mv |
AT marilinskoch hsv1oncolyticvirusesfrombenchtobedsideanoverviewofcurrentclinicaltrials AT seanelawler hsv1oncolyticvirusesfrombenchtobedsideanoverviewofcurrentclinicaltrials AT eantoniochiocca hsv1oncolyticvirusesfrombenchtobedsideanoverviewofcurrentclinicaltrials |
_version_ |
1724413723887534080 |